Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Stadtmauer, Edward A  [Clear All Filters]
2023
Landsburg DJ, Nasta SD, Svoboda J, Gerson JN, Schuster SJ, Barta SK, Chong EA, Difilippo H, Weber E, Cunningham K, et al. Survival outcomes for patients with relapsed/refractory aggressive B cell lymphomas following receipt of high dose chemotherapy/autologous stem transplantation and/or chimeric antigen receptor-modified T cells. Transplant Cell Ther. 2023.
2021
Stadtmauer EA, Sullivan KM, Idrissi MEl, Salaun B, Alonso AAlonso, Andreadis C, Anttila V-J, Bloor AJc, Broady R, Cellini C, et al. Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice. Hum Vaccin Immunother. 2021:1-11.
2020
Bair SM, Brandstadter JD, Ayers EC, Stadtmauer EA. Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy. Cancer. 2020.
Foss FM, Wang XVictoria, Luger SM, Jegede O, Miller KB, Stadtmauer EA, Whiteside TL, Avigan DE, Gascoyne RD, Arber D, et al. Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902. Transfusion. 2020.
2019
Bastidas A, de la Serna J, Idrissi MEl, Oostvogels L, Quittet P, López-Jiménez J, Vural F, Pohlreich D, Zuckerman T, Issa NC, et al. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial. JAMA. 2019;322(2):123-133.
2018
Ziegler M, Landsburg D, Pegues D, Bilker W, Gilmar C, Kucharczuk C, Gorman T, Bink K, Moore A, Fitzpatrick R, et al. Fluoroquinolone prophylaxis is highly effective for the prevention of central line-associated bloodstream infections in autologous stem cell transplant patients. Biol Blood Marrow Transplant. 2018.
2015
Garfall AL, Maus MV, Hwang W-T, Lacey SF, Mahnke YD, J Melenhorst J, Zheng Z, Vogl DT, Cohen AD, Weiss BM, et al. Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. N Engl J Med. 2015;373(11):1040-1047.
Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015.
Paul TM, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ, Tsai DE, Nasta SD, Loren A, Frey N, et al. Outpatient Autologous Stem Cell Transplantation for Patients With Myeloma. Clin Lymphoma Myeloma Leuk. 2015.
2014
Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Xu YYan, Kalos M, Cai L, Bin Fang H-, Weiss BM, Badros A, et al. Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells. Clin Cancer Res. 2014.
Reshef R, Hexner EO, Loren AW, Frey NV, Stadtmauer EA, Luger SM, Mangan JK, Gill SI, Vassilev P, Lafferty KA, et al. Early donor chimerism levels predict relapse and survival after allogeneic stem-cell transplantation with reduced intensity conditioning. Biol Blood Marrow Transplant. 2014.
Landsburg DJ, Vogl DT, Plastaras JP, Stadtmauer EA. Melphalan/Total Body Irradiation-Conditioned Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients With Primary Plasma Cell Leukemia. Clin Lymphoma Myeloma Leuk. 2014.